Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have earned an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $38.2143.

A number of research analysts have weighed in on the stock. Truist Financial assumed coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Weiss Ratings lowered Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Finally, HC Wainwright raised their target price on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Private Wealth Group LLC increased its holdings in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares during the last quarter. V Square Quantitative Management LLC bought a new position in Genmab A/S during the first quarter worth about $34,000. Brown Brothers Harriman & Co. boosted its position in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. Finally, Founders Capital Management increased its stake in shares of Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $28.72 on Friday. Genmab A/S has a 52-week low of $21.00 and a 52-week high of $35.43. The company has a 50-day simple moving average of $26.62 and a 200 day simple moving average of $28.42. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The company has a market capitalization of $17.91 billion, a PE ratio of 21.76, a price-to-earnings-growth ratio of 1.84 and a beta of 0.84.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.